info@bblsa.com   +1.617.236.0954

Back Bay Life Science Advisors in Xconomy

Xconomy recently reported that Gossamer Bio will return to a conventional IPO approach: “With SEC Reopened, Gossamer Bio Turns Back from Alternative IPO Path.”

Back Bay managing director and M&A expert, Vasilios Kofitsas noted that “a company that decides to take the fixed-price route is likely very comfortable with its valuation—and with its disclosures to investors.  

There’s certainly risk from a company perspective should you go this route and price successfully – and the SEC comes back and notices it has issues with lack of disclosures, for example.

. . . also, there is market risk: Investors have to be really comfortable with your disclosures as well. This is a risk you don’t take in a traditional IPO, since it has been cleared by the SEC, for all intents and purposes.”

Read about Gossamer Bio at Xconomy.com.

Related links:

Xconomy – With SEC Reopened, Gossamer Bio Turns Back from Alternative IPO Path

Comments are closed.